ReviewCurrent oncology reports2017
Immune Checkpoint Inhibitors in Gliomas.
Review in Current oncology reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 37 citations in OpenAlex.
- Genomic analysis of primary and recurrent gliomas reveals clinical outcome related molecular features.Scientific reports · 2019Trial
- Identification of Methylstat as a Potential Therapeutic Agent for Human Glioma Cells by Targeting Cell Cycle Arrest.Pharmaceuticals (Basel, Switzerland) · 2025Article
- ELK4 induced upregulation of HOMER3 promotes the proliferation and metastasis in glioma via Wnt/β-catenin/EMT signaling pathway.Biology direct · 2025Article
- Overcoming immune evasion with innovative multi-target approaches for glioblastoma.Frontiers in immunology · 2025Review
- Macrophage polarization-related gene signature for risk stratification and prognosis of survival in gliomas.Journal of cellular and molecular medicine · 2024Article
- Redox-responsive polymer micelles co-encapsulating immune checkpoint inhibitors and chemotherapeutic agents for glioblastoma therapy.Nature communications · 2024Article
- The Potential Significance of the EMILIN3 Gene in Augmenting the Aggressiveness of Low-Grade Gliomas is Noteworthy.Cancer management and research · 2024Article
- Identification of an energy metabolism-related six-gene signature for distinguishing and forecasting the prognosis of low-grade gliomas.Annals of translational medicine · 2023Article
- Significance of NotchScore and JAG1 in predicting prognosis and immune response of low-grade glioma.Frontiers in immunology · 2023Article
- PLEKHA4 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Glioma.BioMed research international · 2023Article
- BRD4: An emerging prospective therapeutic target in glioma.Molecular therapy oncolytics · 2021Review
- TUBA1C is a Prognostic Marker in Low-grade Glioma and Correlates with Immune Cell Infiltration in the Tumor Microenvironment.Frontiers in genetics · 2021Article
- Spider venom components decrease glioblastoma cell migration and invasion through RhoA-ROCK and NaCancer cell international · 2020Article
- Profiling of inhibitory immune checkpoints in glioblastoma: Potential pathogenetic players.Oncology letters · 2020Article
- PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Review
- Top ten discoveries of the year: Neurooncology.Free neuropathology · 2020Article
- Changing paradigms for targeted therapies against diffuse infiltrative gliomas: tackling a moving target.Expert review of neurotherapeutics · 2019Review
- Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade.Neurosurgery · 2019Article
- CD276 and the gene signature composed of GATA3 and LGALS3 enable prognosis prediction of glioblastoma multiforme.PloS one · 2019Article
- Anti-cancer effects of the HuR inhibitor, MS-444, in malignant glioma cells.Cancer biology & therapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewMalignant gliomas result in disproportionately high morbidity and mortality compared with other primary tumors, and progression of disease is inevitable. Novel therapies to improve outcomes are needed and immune checkpoint inhibitors hold significant promise. RECENT
findingsA limited body of preclinical evidence suggests that checkpoint inhibitors may be effective treatment for gliomas. Biomarkers to identify characteristics of gliomas responsive to these therapies will be essential. These may include mismatch repair deficiency and high mutational load that might be germline, somatic, or acquired after therapy. Evidence on the use of immune checkpoint inhibitors in gliomas is evolving. Clinical trials are underway and results are eagerly awaited. Understanding the role of immune checkpoint inhibitors in combination with other treatment modalities for gliomas is crucial to the improvement of outcomes. The design and conduct of future clinical trials need to account for increasingly complex treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.